ストックスクリーナーアプリを入手
1.1601
0.00%
0.0099
前日終値:
$1.17
開ける：
$1.15
24時間の取引高:
45,897
Relative Volume:
0.91
時価総額：
$19.38M
収益：
-
当期純損益:
$-52.53M
株価収益率:
-0.2922
EPS:
-3.97
ネットキャッシュフロー:
$-39.93M
1週間 パフォーマンス:
-7.14%
1か月 パフォーマンス:
-16.43%
6か月 パフォーマンス:
-19.86%
1年 パフォーマンス:
-43.20%
1日の値動き範囲:
$1.14
$1.17
1週間の範囲:
$1.14
$1.2898
52週間の値動き範囲:
$1.105
$2.17
Unity Biotechnology Inc Stock (UBX) Company Profile
名前
Unity Biotechnology Inc
セクター
電話
(650) 416-1192
住所
285 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA
UBX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| UBX | 1.17 | 19.38M | 0 | -52.53M | -39.93M | -3.97 |
| VRTX | 449.37 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.04 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 595.85 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.02 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.14 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Unity Biotechnology Inc Stock (UBX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-01-04 | アップグレード | ROTH Capital | Neutral → Buy |
| 2021-11-10 | アップグレード | Mizuho | Neutral → Buy |
| 2021-06-28 | アップグレード | Citigroup | Sell → Buy |
| 2021-06-07 | 開始されました | H.C. Wainwright | Buy |
| 2021-02-16 | ダウングレード | Citigroup | Neutral → Sell |
| 2020-08-18 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-08-18 | ダウングレード | Mizuho | Buy → Neutral |
| 2020-08-18 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-08-17 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2020-07-28 | 開始されました | ROTH Capital | Buy |
| 2019-12-12 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-03-07 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-09-07 | 開始されました | Mizuho | Buy |
| 2018-05-29 | 開始されました | Citigroup | Buy |
| 2018-05-29 | 開始されました | Goldman | Neutral |
| 2018-05-29 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Unity Biotechnology Inc (UBX) 最新ニュース
Frazier Life Sciences Appoints John Smither and Jim Williams as Senior Advisors - BioSpace
Alyeska Investment Group L.P.'s Strategic Acquisition in Unity B - GuruFocus.com
Unity Biotechnology's CFO sells shares worth $175 - Investing.com India
Unity Biotechnology's chief legal officer sells shares worth $192 - Investing.com
Unity Biotechnology's CFO sells shares worth $175 By Investing.com - Investing.com Canada
Unity Biotechnology's chief legal officer sells shares worth $192 By Investing.com - Investing.com Canada
Unity Biotechnology stock hits 52-week low at $1.15 - Investing.com
Unity Biotechnology CEO Anirvan Ghosh sells $557 in stock By Investing.com - Investing.com UK
Unity Biotechnology stock hits 52-week low at $1.15 By Investing.com - Investing.com Canada
Is Unity Biotechnology (NASDAQ:UBX) In A Good Position To Invest In Growth? - Simply Wall St
Unity Biotechnology Focuses on Promising DME Treatment - TipRanks
Dyadic to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 - The Manila Times
UNITY Biotechnology, Inc. Reports Third Quarter 2024 Financial Results and Business Updates - GlobeNewswire
Age-related Macular Degeneration Market Size is Set for Rapid - openPR
Wet Age-Related Macular Degeneration Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Empery Asset Management LP Acquires Shares in Tonix Pharmaceuticals - Yahoo Finance UK
First patient dosed at the Tokyo Medical Center by Belite Bio in Phase 2/3 DRAGON II clinical trial - Ophthalmology Times
Empery Asset Management, LP Acquires Shares in Volcon Inc - Yahoo Finance UK
Empery Asset Management's Strategic Acquisition in Elevation Oncology - Yahoo Finance
Empery Asset Management's Strategic Reduction in Sharps Technology Inc - Yahoo Finance
To Reverse Aging’s Clock, Adjust the Cell’s Machinery - Genetic Engineering & Biotechnology News
UNITY Biotechnology to Host In-Person Ophthalmology Day in New York on Tuesday, October 15, 2024 - GlobeNewswire
Unity Biotechnology (FRA:9U90) Cash Ratio : 3.85 (As of Jun. 2024) - GuruFocus.com
Jefferies Financial Group Boosts United Therapeutics (NASDAQ:UTHR) Price Target to $432.00 - Defense World
Tri Locum Partners LP Makes New Investment in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Epoch Investment Partners Inc. Increases Stake in United Therapeutics Co. (NASDAQ:UTHR) - Defense World
United Therapeutics Co. (NASDAQ:UTHR) Shares Acquired by Mercer Global Advisors Inc. ADV - Defense World
Symmetry Investments LP Makes New Investment in United Therapeutics Co. (NASDAQ:UTHR) - Defense World
American Century Companies Inc. Has $13.14 Million Position in United Therapeutics Co. (NASDAQ:UTHR) - Defense World
Pacer Advisors Inc. Grows Holdings in United Therapeutics Co. (NASDAQ:UTHR) - Defense World
Meiji Yasuda Asset Management Co Ltd. Buys 33 Shares of United Therapeutics Co. (NASDAQ:UTHR) - Defense World
Longevity and Anti-Senescence Therapy Market Share, Size, Growth, and Forecast to 2031 - InsightAce Analytic
Inspire Investing LLC Acquires 2,936 Shares of United Therapeutics Co. (NASDAQ:UTHR) - Defense World
Uniti Group Inc [UNIT] stock was sold by Mudry Ronald J. at the price of US$0.11 million - Knox Daily
1,054 Shares in United Therapeutics Co. (NASDAQ:UTHR) Bought by Choreo LLC - Defense World
Quest Partners LLC Has $89,000 Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR) - Defense World
Liquidia Corp faces renewed legal challenge from United Therapeutics By Investing.com - Investing.com Australia
Meeder Advisory Services Inc. Invests $36,000 in Uniti Group Inc. (NASDAQ:UNIT) - Defense World
Unity Software Inc. (NYSE:U) Shares Bought by Daiwa Securities Group Inc. - Defense World
Commonwealth Equity Services LLC Has $1.16 Million Position in Unity Software Inc. (NYSE:U) - Defense World
Court rules against United Therapeutics in Liquidia case - Investing.com India
Royal London Asset Management Ltd. Boosts Stake in Unity Software Inc. (NYSE:U) - Defense World
694 Shares in United Therapeutics Co. (NASDAQ:UTHR) Purchased by Caprock Group LLC - Defense World
Anti-Senescence Therapy Market is Likely to Upsurge at USD 25.16 Bn- Unity Biotechnology, OisinBiotechnologies, AgeX Therapeutics, Siwa – Daily News Mirror - Daily News Mirror
The Top 8 Things to Know About Anti-Aging Research Right Now - upworthyscience.com
UBX (Unity Biotechnology) Debt-to-Equity : 1.10 (As of Jun. 2024) - GuruFocus.com
Billionaires are spending big so they — and maybe you — can live forever - MarketWatch
Unity Biotechnology (FRA:9U90) Net-Net Working Capital : €0.01 (As of Jun. 2024) - GuruFocus.com
UBX (Unity Biotechnology) EV-to-Revenue : (As of Aug. 18, 2024) - GuruFocus.com
UBX (Unity Biotechnology) EPS (Basic) : $-1.74 (TTM As of Jun. 2024) - GuruFocus.com
UBX (Unity Biotechnology) COGS-to-Revenue : 0.00 (As of Jun. 2024) - GuruFocus.com
Unity Biotechnology Inc (UBX) 財務データ
収益
当期純利益
現金流量
EPS
1.80%
0.42%
大文字化:
|
ボリューム (24 時間):